Information Provided By: 
Fly News Breaks for July 7, 2016
ALXN
Jul 7, 2016 | 09:27 EDT
After Alexion posted the slides from the REGAIN study presentation, Piper Jaffray analyst Joshua Schimmer still believes the dataset is approvable for Soliris in refractory myasthenia gravis. Despite missing the primary endpoint, multiple key secondary endpoints were hit and it appears there is a subset of patients with very meaningful benefit from therapy, Schimmer tells investors in a research note. He has an Overweight rating on the shares.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
